UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 21, 2019
ANIXA BIOSCIENCES, INC.
(Exact name of registrant as specified in its charter)
Delaware | 000-11254 | 11-2622630 |
(State or other jurisdiction | (Commission | (IRS Employer Identification No.) |
3150 Almaden Expressway, Suite 250 San Jose, CA | 95118 |
(Address of principal executive offices) | (Zip Code) |
Registrants telephone number, including area code: (408) 708-9808
(Former name or former address, if changed since last report)
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
| Trading Symbol(s) |
| Name of each exchange on which registered |
Common Stock, par value $0.01 per share |
| ANIX |
| The NASDAQ Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
1
Item 8.01 Other Events.
On August 21, 2019, Anixa Biosciences, Inc. (the Company) and certain of its current and former officers and directors entered into a settlement agreement with a stockholder of the Company to resolve a lawsuit brought derivatively on behalf of the Company in the Delaware Court of Chancery (the Derivative Action) on the terms set forth in the enclosed Notice of Pendency of Settlement of Action. As a result of the settlement, all of the claims asserted in the Derivative Action will be dismissed.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
99.1 Notice of Pendency of Settlement of Action
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: August 27, 2019 |
| |
ANIXA BIOSCIENCES, INC. | ||
By: | /s/ Amit Kumar | |
Name: Dr. Amit Kumar | ||
Title: President and Chief Executive Officer |
3